3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
12
Tumor-Agnostic
6
Gastrointestinal
4
Genitourinary
2
Breast
2
Sarcoma
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Sarcoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Neoplasms
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Colonic Diseases
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Bronchogenic
1
Bronchial Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
lutetium Lu 177 dotatate
18
Everolimus
13
Temozolomide
12
Nivolumab
10
pembrolizumab
9
cabozantinib
8
Capecitabine
8
Sunitinib
7
lenvatinib
5
Magnetic Resonance Spectroscopy
5
Etoposide
5
lanreotide
4
gallium Ga 68 dotatate
4
Specimen Handling
4
Ipilimumab
4
Cisplatin
4
Carboplatin
4
177Lu-octreotide, DOTA(0)-Tyr(3)-
4
telotristat ethyl
3
surufatinib
3
pazopanib
3
avelumab
3
Octreotide
3
Injections
3
Fluorodeoxyglucose F18
3
Cyclophosphamide
3
Bevacizumab
3
sintilimab
2
fosbretabulin
2
fludarabine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
alectinib
×
NET
×
Clear all
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts